Within the tumor microenvironment (TME), STING pathway activation in antigen-presenting cells leads to increased production of type I interferons and promotes tumor-mediated cross priming of CD8+ T cells, finally resulting in adaptive anticancer immune responses [31, 32]. This evidence concerns the gene STING1 and neoplasm.